Ligase BioPartners is a life sciences venture builder fund dedicated to advancing breakthrough oncology innovations. We partner with exceptional scientists developing therapeutics, diagnostics, and platforms that meaningfully improve patient lives.
The Ligase BioPartners team brings decades of expertise in life sciences venture capital, strategic guidance, and operational support needed to accelerate development of early stage innovation.
Cheryl is the former Investment Director at M Ventures, where she led Seed and Series A investments in Calypso Biotech, Rewind Therapeutics, Outrun Therapeutics, Multitude Therapeutics, ImmuneBridge, and several other emerging life science companies.
Her track record includes successful exits such as Calypso (acquired by Novartis) and VAXXIM (acquired by NEC/BCME). Cheryl holds a Ph.D. in Oncology from the University of Amsterdam and serves on the Board of Directors of Laigo Bio.
Shobhit is the former Managing Director of the Oncode Oncology Bridge Fund I, where he built and financed early-stage therapeutic and platform companies emerging from the Oncode Institute. Previously, he was an Investment Manager at Amsterdam Academic Ventures, focusing on company creation and early financings across life sciences and technology.
Shobhit holds a Ph.D. in Immunology from the University of Amsterdam and serves on the Board of Directors of sCellgen, 51x Therapeutics, Genase Therapeutics, and Simmunext Biotherapeutics.
Ligase BioPartners intends to operate under the AFM registration regime for small managers. In line with applicable European regulations (including the PRIIPs Regulation and the SFDR), we make key investor information available on this website.
You can download the main documents here:
The information on this website is provided for informational purposes only and does not constitute investment advice, an offer, or a solicitation to invest in any fund or product.
To share an opportunity, explore collaboration, or learn more about Ligase BioPartners, please reach out using the form below.